- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 53
- States / cities
- Anaheim, California • Escondido, California • Riverside, California + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 4,710
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Imexon + docetaxel
- Drug
- Lead sponsor
- AmpliMed Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Dallas, Texas
- Conditions
- Cancer
- Interventions
- immunological diagnostic method, physiologic testing
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- Vorinostat, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Stanford, California • Tampa, Florida
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Interventions
- LY2584702, Erlotinib, Everolimus
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Covid19, Cytokine Storm, Mechanical Ventilation Complication
- Interventions
- Anakinra, 0.9% Saline
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19
- Interventions
- Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
- Interventions
- Tiotropium
- Drug
- Lead sponsor
- ThomasTruncale
- Other
- Eligibility
- 40 Years to 80 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Tampa, Florida
- Conditions
- COPD
- Interventions
- Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Albany, New York • Cleveland, Ohio
- Conditions
- Chronic Low Back Pain
- Interventions
- Naproxen, Placebo, Omeprazole
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Infant, Newborn, Diseases, Hypoxia
- Interventions
- Oxygen Environment, Nasal Cannula Oxygen
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Hour to 6 Months
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cancer
- Interventions
- docetaxel, thalidomide
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cough
- Interventions
- Voice Therapy, Voice Therapy and Heart Rate Variability Biofeedback, Heart Rate Variability Biofeedback
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Cystic Fibrosis, Growth Failure, Exocrine Pancreatic Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 3 Months
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 24 more
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
- Interventions
- Home hospital care
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
- Interventions
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Mucus Clearance, Respiratory Symptoms, Breathlessness, Chest Mucus Accumulation, Low Energy Levels
- Interventions
- BetterLungs, Placebo
- Dietary Supplement
- Lead sponsor
- The Better Brand Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Time Restricted Eating, Obstructive Sleep Apnea
- Interventions
- Time restricted eating
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
- Drug · Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Perinatal Stroke, Hypoxic-ischemic Encephalopathy, White Matter Injury
- Interventions
- Increased protein
- Dietary Supplement
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Days to 3 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD
- Interventions
- Pulmonary rehabilitation program
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
- Interventions
- Administration of autologous adipose derived SVF
- Procedure
- Lead sponsor
- Elliot Lander
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Rancho Mirage, California
- Conditions
- Malaria, Diarrhea, Pneumonia
- Interventions
- Not listed
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia